Rise Advisors’s Sagimet Biosciences SGMT Stock Holding History

Rise Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-306	Closed	-$2.1K	–	1198
2025 Q3	$2.1K	Hold	306	–	–	﹤0.01%	1188
2025 Q2	$2.33K	Buy	+306	New	+$1.29K	﹤0.01%	1188

Other funds holding SGMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rise Advisors's SGMT Position: Q4 2025 in Review

Rise Advisors sold out of Sagimet Biosciences (SGMT) in Q4 2025, closing a stake of 306 shares — an estimated $2.1K sold.

Rise Advisors first reported a position in SGMT in Q2 2025 and held it in 2 quarters. The position peaked at $2.33K in Q2 2025. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

Rise Advisors reported no remaining Sagimet Biosciences position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 306 Sagimet Biosciences shares in Q4 2025, an estimated $2.1K.
Rise Advisors first reported a position in Sagimet Biosciences in Q2 2025 and held it in 2 quarters.
Rise Advisors's Sagimet Biosciences position peaked at $2.33K in Q2 2025.
86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.